Search
Enalapril
go.drugbank.com/drugs/DB00584ApprovedInvestigationalVet approvedCommonly marketed under the trade name Vasotec, enalapril was first approved by the FDA in 1985 for the management of hypertension, heart failure, and asymptomatic left ventricular dysfunction.
Pemetrexed
go.drugbank.com/drugs/DB00642ApprovedInvestigationalPemetrexed was first approved by the FDA in February 4, 2004.[A253907] … Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta.
Sotalol
go.drugbank.com/drugs/DB00489ApprovedInvestigationalSotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tabl...
Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.
Bioallethrin
go.drugbank.com/drugs/DB13746ApprovedWithdrawnA mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin.
Ethosuximide
go.drugbank.com/drugs/DB00593ApprovedInvestigationalAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Platelet-activating factor acetylhydrolase
go.drugbank.com/bio_entities/BE0002409TargetHumansLipoprotein-associated calcium-independent phospholipase A2 involved in phospholipid catabolism during inflammatory and oxidative stress response (PubMed:10066756, PubMed:16371369, PubMed:17090529, PubMed:2040620, PubMed:7700381, PubMed:...
Synonyms: Group-VIIA phospholipase A2Factor IX Complex (Human)
go.drugbank.com/drugs/DB11330ApprovedInvestigationalAs the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients
Nisoldipine
go.drugbank.com/drugs/DB00401ApprovedIt acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction.